# Selective Fat Redistribution and Local Fat-Targeting Methods

Status: third-pass verification complete (2026-04-14). Prior passes were done by an earlier assistant; this pass independently re-verified aminophylline, adipotide, and audited every other claim file against primary sources.

## Third-pass corrections and additions (2026-04-14)

Applied to existing claim files:

- **Aminophylline (c007)**: Added explicit "deficit-dependent rate-modulator" claim backed by Greenway/Bray 1995 Trials 5 and 6 (no-diet sub-trials, null/minimal). Added mechanism clarification: topical aminophylline raises cAMP via PDE inhibition; the depot-selectivity story lives at the alpha-2/Gi level (female gluteofemoral fat is alpha-2-rich, Gi normally brakes cAMP, PDE inhibition bypasses that brake), NOT at direct alpha-2 antagonism — aminophylline is not an alpha-2 antagonist; yohimbine is. Flagged the confound that Collis 1999 is BOTH the only double-blind placebo trial AND the only no-deficit trial, so "needs a deficit" and "fails on proper blinding" predict the same null. Softened FTC-enforcement framing (no named-defendant case verified).
- **Adipotide (c006)**: Added named vendor ecosystem (Peptide Sciences, Core Peptides, BehemothLabz, and ~7 others as of 2026), dominant forum dose protocol (primate-scaled ~0.43 mg/kg/day SC × 28 days), and the observation that a decade of underground availability has produced essentially no convincing efficacy logs. Added the Bostin Loyd case (publicly attributed stage-5 CKD to adipotide self-use at ~5 mg/day; died 2022 with documented end-stage renal disease) as the loudest real-world safety signal, with the polypharmacy confound noted honestly. Added the Shaman-Australis self-log (50 mg/day, 3.5 kg/2 wk, cloudy urine, severe hypoglycemia). Added the steelman for mechanism interest (vascular ablation is orthogonal to GLP-1 and yohimbine mechanisms; primate data favored enlarged/visceral adipocytes).
- **Cryolipolysis PAH arithmetic (c004, c018, summary)**: Changed "40-100x higher than 1 in 20,000" to "~40x at the meta-analytic mean, up to ~90x at the confidence interval upper bound." The original upper bound was not supported by the headline point estimate.
- **HIFEM (c016)**: Samuels 2022 follow-up attrition clarified: 61% lost to 6-month, explicitly attributed by authors to COVID-19 disruption. The "60% dropout" framing is directionally right but should include the COVID context.
- **c013 low-value bucket**: Added skeptical one-liners for yohimbine (interesting alpha-2 mechanism, human-evidence-weak), AOD9604 (failed Phase 2B, now a research peptide), 5-amino-1MQ (preclinical-only NNMT inhibitor), and topical capsaicin / synephrine / forskolin (not depot-selective tools).
- **Hernandez 2011 redistribution detail (c003, summary)**: "Upper abdomen" is directly supported by the primary paper; "shoulders and triceps" appears in press coverage rather than in the paper's results text, so should be cited as press-coverage paraphrase.

What this pass did NOT find:

- No fabricated PMIDs or URLs in c001-c018 on the sample I rechecked.
- No mechanism swaps (deoxycholic acid vs phosphatidylcholine handled correctly; Liposonix vs UltraShape distinguished; laser-assisted lipo vs SculpSure vs LLLT distinguished).
- No large number errors. Caruso n=50 (already corrected in second pass); Samuels follow-up attrition; PAH multiplier are the only numbers adjusted.
- CBL-514 Phase 2b (76.7% vs 18.9% responder rate at 12 weeks) and Caliway Phase 3 status confirmed.
- FDA January 2024 Aqualyx / Lipodissolve consumer safety communication is real but the FDA landing page is difficult to fetch directly; secondary coverage places it late January 2024. Kept "January 2024" framing.

Added as possible cross-references worth considering but not added as primary compounds:

- **Retatrutide (GIP/GLP-1/glucagon triagonist)** Phase 2 substudy: preferential visceral adipose tissue reduction (e.g., 24.5-39.1% VAT vs 13.2-43.5% ASAT at 48 weeks across doses). This is arguably the cleanest current "selective fat redistribution" signal in medicine and lives in the incretin-medication track rather than the local-body-contouring track. Source: Lancet Diabetes Endocrinol 2025, https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract.

## Key takeaways (second pass)

- The honest single sentence: among methods in and around the April 13 draft, only `liposuction`, `cryolipolysis`, `thermal HIFU / non-thermal focused ultrasound`, `laser-assisted liposuction`, `hyperthermic 1060 nm laser (SculpSure-class)`, and `deoxycholic-acid injection (submental)` have real human evidence for permanent local adipocyte removal or destruction. Everything else in the draft is contour change, transient circumference effect, cellulite marketing, disproven spot reduction, or abandoned/experimental.
- Even the best of those methods do not produce durable whole-body fat redistribution without concurrent energy balance control. `Hernandez 2011` and `Benatti 2012` report that total fat regained after liposuction preferentially reaccumulates in upper abdomen, trunk, and visceral depots. The treated area stays smaller but the body's total fat budget does not improve.
- The April 13 draft overweights topical and supplement leads relative to their evidence, and understates the importance of several comparator methods (HIFU, laser-based modalities, off-label body-area DCA, PAH risk detail, and the PPC/lipodissolve regulatory record).
- `Adipotide` is best described as an abandoned clinical candidate, not as an experimental option. Its single human trial was terminated in January 2019 after enrolling only 4 patients over 6.5 years, no results were ever posted, and no peer-reviewed human efficacy or safety publication exists.
- Ranked by adversarial scrutiny of the evidence, the current state is:
  1. `Liposuction` — definite local adipocyte removal, limited metabolic benefit, credible compensatory redistribution signal, modern mortality ~1 per 11,000 in accredited facilities.
  2. `Cryolipolysis` — modest local reduction, material paradoxical adipose hyperplasia risk (~0.22% per patient in 2025 meta-analysis, roughly 40x higher than the "1 in 20,000" figure in marketing).
  3. `Deoxycholic acid (submental)` — Phase 3 RCT-supported submental efficacy, common local AEs including marginal mandibular nerve paresis and dysphagia.
  4. `Thermal HIFU / focused ultrasound (Liposonix, UltraShape Power)` — histologic adipocyte destruction but sham-subtracted effect small (~1 cm waist); inferior to cryolipolysis head-to-head; Liposonix largely displaced commercially.
  5. `Laser-assisted liposuction (SmartLipo, SlimLipo)` — liposuction variant; possibly better skin tightening; signature risk is internal thermal burns (~1-6% depending on device).
  6. `Hyperthermic 1060 nm laser (SculpSure)` — niche peer of cryolipolysis, biologically plausible, ~1 mm / ~8% fat thickness reduction at 12 weeks, blinded-observer performance barely above chance.
  7. `Radiofrequency electric-field (Vanquish, TruSculpt, Emsculpt NEO RF component)` — modest contour effects, industry-dominated literature, effects near measurement error for many platforms.
  8. `Off-label body-area deoxycholic acid (abdomen, flanks, arms)` — mechanism plausible, Level-of-evidence low (case series and small cohorts), not an RCT-grade recommendation.
  9. `Topical aminophylline` — the cleanest independent placebo-controlled trial (Collis 1999) was null; the positive literature leans heavily on Greenway/Bray patent holders and on Caruso 2007 which was open-label.
  10. `Topical caffeine` — cellulite-oriented literature, null or industry-linked independent trials, no imaging evidence of local adipocyte loss.
  11. `Glycyrrhetinic acid` — one small unreplicated 2005 trial.
  12. `ALCAR / carnitine` — at most a small nonspecific weight-management helper; no selective-fat-redistribution evidence.
  13. `HIFEM / Emsculpt (HIFEM-only)` — primarily muscle hypertrophy; any fat signal is indirect, quantitatively small, and the evidence is >85% industry-author-affiliated.
  14. `Selective muscle training / spot reduction` — null on meta-analysis; two small positive "local work + cardio" trials suggest a marginal hedge, not a real lever.
  15. `Low-level / "cold" laser therapy (Zerona, Erchonia)` — industry-dominated positive trials, contradicted by the one independent mechanism study; treat as hype.
  16. `Adipotide` — abandoned clinical candidate, not experimental option.
  17. `Classical PPC "Lipostabil" / Lipodissolve / lipolytic mesotherapy` — regulator-banned or regulator-warned, AE-prone (including mycobacterial infections), no RCT evidence base.

## Endpoint-quality matrix

| Method | Permanent adipocyte removal | Strongest endpoint quality | Evidence tier |
|---|---|---|---|
| Liposuction | yes, by definition | RCT, DXA, MRI, histology | established |
| Cryolipolysis | yes (apoptosis) | meta-analysis, ultrasound fat thickness, circumference | established |
| DCA (submental) | yes (adipocytolysis) | Phase 3 RCT, clinician + patient scales | established |
| DCA (body, off-label) | yes mechanistically | case series, small cohorts | niche / evidence-weak |
| Thermal HIFU / focused US | yes (necrosis/cavitation) | sham-controlled RCT, circumference | niche but plausible |
| LAL (SmartLipo, SlimLipo) | yes (thermal apoptosis + surgical removal) | case series, one RCT | niche; treat as liposuction variant |
| 1060 nm laser (SculpSure) | yes (thermal apoptosis) | industry single-arm trial, ultrasound fat thickness | niche but plausible |
| RF electric-field | yes (thermal apoptosis) | industry trials, ultrasound | niche; effect near noise |
| Aminophylline topical | no evidence | circumference (mostly); one null ultrasound RCT | weak; downgrade |
| Caffeine topical | no evidence | circumference, cellulite grading | weak; downgrade |
| Glycyrrhetinic acid topical | no evidence | one small ultrasound RCT | weak |
| ALCAR / carnitine oral | no evidence | weak meta-analysis for weight | not a selective-fat tool |
| HIFEM (Emsculpt) | indirect at best | ultrasound, industry-authored | muscle-focused, not fat-removal |
| Spot reduction via exercise | no | null meta-analysis; 2 small positive trials | disproven for pure local work; hedged for local + cardio |
| LLLT (Zerona) | no (independent null) | industry sham-controlled circumference | hype |
| Adipotide | preclinical only | monkey study; no human data | abandoned |
| PPC "Lipostabil" / mesotherapy | mechanism via DC contaminant | case series, AE literature | regulator-warned |

## Effect sizes at a glance

- `Liposuction`: treated depot stays reduced; total body fat returns to baseline within ~1 year without lifestyle change; ~10% visceral fat increase at 6 months in sedentary arm (Benatti 2012).
- `Cryolipolysis`: ~3.56 cm abdominal circumference and ~5.22 mm suprailiac fat thickness at 12 weeks (2025 meta-analysis). PAH ~0.22% per patient (95% CI 0.10-0.47).
- `Thermal HIFU (Liposonix)`: sham-subtracted waist circumference reduction ~1.0-1.1 cm (Jewell 2011). Head-to-head inferior to cryolipolysis.
- `SculpSure 1060 nm`: ~8.5% / ~1.3 mm fat thickness reduction at 12 weeks in industry pivotal trial, no circumference change.
- `DCA (submental)`: significant improvement on clinician + patient scales; ~4% marginal mandibular nerve paresis (all resolved), ~2% dysphagia.
- `Aminophylline topical`: 2023 systematic review is positive but one clean independent placebo RCT (Collis 1999) was null; the best-known positive (Caruso 2007, 11 cm vs 5 cm waist loss at 12 weeks) was open-label with both arms on 1200 kcal + walking.
- `Topical caffeine`: ~2 cm thigh circumference reduction at 30 days in open-label 7% studies; microcirculation endpoints null; independent placebo-controlled cellulite trial null.
- `Spot reduction via exercise`: pooled null (effect size -0.03, 95% CI -0.10 to 0.05); two small matched-EE trials suggest a small local + cardio effect.
- `HIFEM (Emsculpt NEO)`: ~28% ultrasound abdominal fat thickness reduction at 3 months in the single sham-controlled RCT; industry-authored and within plausible ultrasound measurement error at the lower end; ~5.5 mm muscle thickness increase.

## Safety essentials

- `Liposuction`: mortality ~1 per 11,000 in modern accredited-facility series; complications 0.4-0.6%; fat embolism rare but ~33% mortality when it occurs; BBL combinations materially worsen risk.
- `Cryolipolysis`: PAH at ~0.22% per patient (modern meta-analysis), typically requires liposuction to correct; does not spontaneously resolve; elevated in men, with lower-abdomen treatment, and on first-generation applicators.
- `DCA submental`: ~4% marginal mandibular nerve paresis (all resolved), ~2% dysphagia, common local pain/swelling/bruising/induration/numbness/nodules.
- `Injection lipolysis (non-Kybella)`: mycobacterial abscesses, granulomatous panniculitis, chronic painful subcutaneous nodules, skin necrosis, peripheral nerve injury. FDA January 2024 warning against Aqualyx, Lipodissolve, Lipo Lab, Kabelline.
- `LAL`: internal thermal burns 1-6% depending on device.
- `HIFU`: generally favorable; rare focal burns and fat atrophy; facial HIFU has reversible nerve paresis.
- `RF / HIFEM`: mostly transient soreness and erythema; class-level rhabdomyolysis risk from supramaximal-contraction EMS devices exists but is not yet documented specifically for Emsculpt.
- `Topical aminophylline / caffeine`: contact dermatitis (aminophylline via ethylenediamine), systemic absorption minor but real for caffeine.
- `Adipotide`: preclinical renal tubular injury known; human safety undocumented because the trial never progressed.

## Internet-claim corrections (expanded)

- `"Cryolipolysis is essentially risk-free permanent fat removal."` Not accurate. Real effect is modest, PAH per-patient rate is around 0.22% (not 0.005%), and correction typically requires surgery.
- `"Kybella works everywhere on the body."` The established evidence is submental only. Body-area use is off-label case-series evidence and is explicitly not recommended by ASPS.
- `"Lipodissolve / PPC-DC / Aqualyx / Lipo Lab is a safer Kybella alternative."` Most such products are regulator-flagged or FDA-warned. Documented AEs include necrosis, chronic nodules, and mycobacterial abscesses.
- `"Fat-burning creams work if you find the right one."` Independent placebo-controlled evidence for topical aminophylline and caffeine is either null or absent on imaging endpoints. Positive studies cluster in patent-holding or manufacturer-adjacent authorship.
- `"Crunches / targeted exercises reduce local fat."` Meta-analysis is null. A small effect may exist under matched-EE "local + cardio" conditions but is not a useful tool.
- `"Adipotide will let you dissolve fat selectively."` The human trial was terminated after 4 patients in 2019. There is no human efficacy or safety readout.
- `"Emsculpt is a fat-removal device."` It is primarily a muscle-hypertrophy device. Any fat signal is indirect and the evidence base is dominated by the manufacturer's own advisors.
- `"Fat never grows back after liposuction."` The treated depot stays smaller long-term, but total body fat is regained and tends to redistribute to untreated and visceral depots unless diet/exercise are applied.

## What seems missing from the draft

These should be added:

- `Off-label body-area deoxycholic acid` — the draft stops at Kybella-submental. Consumers increasingly hear about abdomen, flanks, and arm injections. The evidence is much weaker than submental, and this should be said explicitly.
- `Phosphatidylcholine / deoxycholate "Lipostabil," Aqualyx, and lipolytic mesotherapy` — the darker pre-Kybella history is relevant context. Brazil banned PPC in 2002; FDA issued a consumer safety communication in January 2024 against Aqualyx, Lipodissolve, Lipo Lab, Kabelline. Gray-market products carry documented mycobacterial infection risk.
- `High-intensity focused ultrasound (Liposonix) and non-thermal focused ultrasound (UltraShape Power)` — real adipocyte destruction, sham-subtracted effect ~1 cm waist, inferior to cryolipolysis. Belongs in the comparator list at a "niche but plausible" tier.
- `Laser-assisted liposuction (SmartLipo / SlimLipo)` — should be briefly mentioned as a liposuction variant; signature risk is internal thermal burns.
- `Hyperthermic 1060 nm laser (SculpSure)` — peer of cryolipolysis, niche but plausible.
- `Low-level / "cold" laser therapy (Zerona, Erchonia)` — belongs as a skeptical sidebar because consumers encounter it. Independent mechanism study directly contradicts local fat loss claims.
- `HIFEM / Emsculpt / Emsculpt NEO` — should be briefly included, but explicitly reframed as a muscle-hypertrophy device whose marketing implies selective fat reduction beyond what the evidence supports.
- `Paradoxical adipose hyperplasia` deep dive — the draft's cryolipolysis section needs to include a specific risk discussion because the discrepancy between old ~0.005% and modern ~0.22% figures is large and consumers are misled by outdated numbers.
- `CBL-514 (Caliway)` — the most credible near-term emerging injectable-lipolytic candidate with 2025 Phase 2b positive data. Not yet approved; worth a brief mention.
- `Visceral-versus-subcutaneous distinction` — the draft implicitly conflates these. Liposuction cannot reach visceral fat; compensatory visceral fat increase is a documented risk after subcutaneous lipectomy in sedentary patients.
- `GLP-1 / incretin cross-reference` — out of primary scope, but incretin mimetics produce substantial visceral and ectopic fat reduction in trials, which is the most reliable "selective" fat loss signal in current medicine. Should briefly cross-reference `research/glp1-antiobesity-meds/_summary.md`.

## What should be downgraded or cut

- `Topical aminophylline` section: downgrade the framing from "seems worth trying, good effect sizes" to "weak-helper tier at best; the cleanest independent placebo-controlled trial (Collis 1999) was null; the best-quoted positive result (Caruso 2007) was open-label with both arms on 1200 kcal + walking; the positive literature is concentrated in Greenway/Bray patent-holding authorship." Cite Collis 1999 explicitly as counter-evidence. Fix the minor factual error: the Caruso study had 50 participants (not 25).
- `Topical caffeine` section: downgrade similarly. State explicitly that the literature is cellulite/cosmetic, that independent mechanism endpoints were null in Lupi 2007, and that the one independent placebo-controlled anti-cellulite cream RCT (Bielfeldt 2016) was null. Remove any language implying topical caffeine is a selective-fat-redistribution tool.
- `Glycyrrhetinic acid` section: keep but shorten and explicitly flag as "one small unreplicated 2005 trial." The draft's "seems not worth pursuing" conclusion is directionally correct; do not spend more space than this deserves.
- `ALCAR` section: cut the selective-fat-redistribution framing. If retained at all, move it to a general supplement discussion in `research/supplements-for-downcycle/`. It is not a local-fat-targeting tool.
- `Adipotide` section: rewrite to explicitly say the program was abandoned. The draft implies current experimental relevance; that is no longer accurate.
- `Selective muscle training / spot reduction` section: the "non-existent" framing is nearly but not quite right. Keep the disproof as central but add a hedged mention of Brobakken 2023 and Paoli 2021 (small positive matched-EE trials for local work + cardio), explicitly framed as "not a major lever; total deficit still dictates fat loss."
- `Radiofrequency` section: expand slightly to note that most of the recent "fat reduction" evidence from combined HIFEM + RF platforms (Emsculpt NEO) is dominated by manufacturer-affiliated authors with effects at or near measurement error.

## Ranking by practical evidence (updated)

1. `Liposuction` — most certain local depot reduction; invasive; contouring-not-metabolic.
2. `Cryolipolysis` — noninvasive, modest local effect, real PAH risk now known to be higher than advertised.
3. `Deoxycholic acid (submental)` — real but indication-limited.
4. `Thermal HIFU / focused ultrasound` — niche but plausible, inferior to cryolipolysis.
5. `Laser-assisted liposuction` — liposuction variant with burn risk.
6. `1060 nm SculpSure` — niche peer of cryolipolysis.
7. `Off-label body-area DCA` — mechanism-plausible, evidence-weak.
8. `RF electric-field (Vanquish / TruSculpt)` — modest effects, industry-dominated.
9. `CBL-514` — experimental; watch list.
10. `Topical aminophylline` — weak-helper at best; cleanest independent trial null.
11. `Topical caffeine` — mostly cellulite/cosmetic; no imaging-based evidence.
12. `Glycyrrhetinic acid` — one small unreplicated trial.
13. `Selective muscle training / spot reduction` — disproven for pure local work; small hedge under matched-EE local + cardio.
14. `HIFEM (Emsculpt alone)` — muscle-hypertrophy device with weak selective-fat claims.
15. `Low-level laser therapy (Zerona)` — hype.
16. `Adipotide` — abandoned.
17. `Classical PPC "Lipostabil" / Lipodissolve / lipolytic mesotherapy` — regulator-warned.

## Scope checklist

- [x] Transcribe relevant local notes from the wiki and archived source files into research-ready claims
- [x] Research each major section from the April 13 draft in more depth
- [x] Separate adipocyte-removal methods from methods that only change fat loss while weight is falling
- [x] Check whether claimed local-fat-loss effects survive controlled trials and replications
- [x] Identify which claims are cosmetic/cellulite literature versus actual adipose-loss evidence
- [x] Add HIFU, laser-based modalities (LAL, SculpSure, LLLT), HIFEM, off-label body DCA, PPC/Lipostabil, PAH deep dive, CBL-514 as comparator sections
- [x] Explicitly flag methodological bias (industry authorship, patent holders, ultrasound noise floors)
- [x] Document effect sizes, limitations, safety, and practical relevance at updated 2024-2026 evidence
- [x] Add explicit "What seems missing from the draft" and "What should be downgraded or cut" sections
- [x] Save blockers and verification notes in the standard project files